A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
for Chronic Obstructive Pulmonary Disease (COPD)
68 locations incl. Cullman
Sponsor: AstraZeneca
Sex: All·Age: 40 - 80
Code: NCT06878261·Phase 3·Recruiting